Simron Singh

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao, Nicola Fazio, Simron Singh et al. · The Lancet · 2015 · 1.3K citations

Medicine, Oncology, Surgery +12

Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes

Julie Hallet, Calvin Law, Moisés Cukier et al. · Cancer · 2014 · 855 citations · Full text

Medicine, Oncology, Pathology +15

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Simron Singh, Daniel Halperin, Sten Myrehaug et al. · The Lancet · 2024 · 324 citations · Full text

Medicine, Oncology, Pharmacology +17

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

Þorvarður R. Hálfdánarson, Jonathan Strosberg, Laura Tang et al. · Pancreas · 2020 · 196 citations

Medicine, Endocrinology, Oncology +15

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

Michael Henke, A. Fortin, Heikki Minn et al. · The Lancet Oncology · 2015 · 162 citations

Medicine, Oncology, Radiation Oncology +12